Understanding systemic lupus erythematosus in the Gullah population

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on systemic lupus erythematosus (SLE), an autoimmune disease that disproportionately affects African Americans, particularly those from the Gullah community in South Carolina and Georgia. The research aims to explore the genetic and environmental factors contributing to the development and progression of SLE in this unique population, which has minimal genetic admixture. Participants will include individuals who self-identify as Gullah and meet specific diagnostic criteria for SLE or are healthy controls. The study seeks to uncover insights that could lead to better understanding and management of SLE in African Americans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 2 years and above;
* Self-identified as African-American "Gullah" from the Sea Island region of South Carolina;
* Have had at least 4 of the 11 diagnostic criteria for SLE as designated by the American College of Rheumatology (ACR), be a relative of a known SLE patient, or be an unrelated healthy Gullah control;
* Ability to speak and understand English;
* Ability and willingness to give informed consent

Exclusion Criteria:

* Race defined by participant as other than Black or African-American;
* Being a prisoner, mentally ill patient, or institutionalized individual;
* Unwilling or unable to give informed consent

Where it's running

• Medical University of South Carolina
  Charleston, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Diane L. Kamen, MD, MSCR — Medical University of South Carolina
• Study coordinator: Diane L. Kamen, MD, MSCR
• Email: kamend@musc.edu
• Phone: 843-792-4825

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.